James E Flynn - Insider Trading Tracker

Aclaris Therapeutics, Inc.

US ˙ NasdaqGS ˙ US00461U1051

Introduction

This page provides a comprehensive analysis of the known insider trading history of James E Flynn. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate James E Flynn has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:LRMR / Larimar Therapeutics, Inc.	Director, 10% Owner	7,321,129
US:SPRY / ARS Pharmaceuticals, Inc.	10% Owner	4,887,254
US:NUVL / Nuvalent, Inc.	Director, 10% Owner	2,647
US:PHGE / BiomX Inc.	Director	1,247,054
	10% Owner	897,587
US:AHCO / AdaptHealth Corp.	10% Owner	11,528,863
US:GUTS / Fractyl Health, Inc.	10% Owner	834,254
US:CMAX / CareMax, Inc.	Director, 10% Owner	12,123
US:DALS / DA32 Life Science Tech Acquisition Corp - Class A	Director, 10% Owner	0
US:AFIB / Acutus Medical, Inc.	Director	20,822
US:ONCR / Oncorus, Inc.	10% Owner	284,697
US:FLAC / Frazier Lifesciences Acquisition Corp - Class A	10% Owner	2,480,199
US:MIRM / Mirum Pharmaceuticals, Inc.	10% Owner	1,540,190
US:PEPG / PepGen Inc.	10% Owner	0
US:DFPH / DFP Holdings Limited	10% Owner	625,000
US:XLO / Xilio Therapeutics, Inc.	10% Owner	0
US:OMIC / Singular Genomics Systems, Inc.	10% Owner	0
US:HOWL / Werewolf Therapeutics, Inc.	10% Owner	0
US:EWTX / Edgewise Therapeutics, Inc.	10% Owner	0
US:TERN / Terns Pharmaceuticals, Inc.	10% Owner	0
US:IGNYU / Ignyte Acquisition Corp - Units (1 Ord & 1/2 War)	10% Owner	725,000
US:LUMO / Lumos Pharma, Inc.	10% Owner	784,568
US:GRAY / Graybug Vision Inc	10% Owner	0
US:ANNX / Annexon, Inc.	10% Owner	0
US:NKTX / Nkarta, Inc.	10% Owner	0
US:GBIO / Generation Bio Co.	10% Owner	0
US:RVMD / Revolution Medicines, Inc.	10% Owner	0
US:SDGR / Schrödinger, Inc.	10% Owner	0
US:BDTX / Black Diamond Therapeutics, Inc.	10% Owner	0
US:FIXX / Homology Medicines, Inc.	10% Owner	0
US:CABA / Cabaletta Bio, Inc.	10% Owner	0
US:FREQ / Frequency Therapeutics Inc	10% Owner	0
US:ACRS / Aclaris Therapeutics, Inc.	10% Owner	3,159,165
US:SWAV / Shockwave Medical, Inc.	10% Owner	0
	10% Owner	856,470
US:ARVN / Arvinas, Inc.	10% Owner	0
	10% Owner	0
US:AERI / Aerie Pharmaceuticals Inc	10% Owner	9,719,503
US:AVDL / Avadel Pharmaceuticals plc	10% Owner	952,265
US:PRTO / Proteon Therapeutics, Inc.	Director	12,700
US:KNSA / Kiniksa Pharmaceuticals, Ltd.	10% Owner	0
US:MNK / Mallinckrodt PLC	10% Owner	17,242,766
US:148CVR012 / CONTRA CVR CATALYST	10% Owner	305,965
US:RYTM / Rhythm Pharmaceuticals, Inc.	10% Owner	0
US:REPH / Societal CDMO Inc	10% Owner	1,176,685
US:EHTH / eHealth, Inc.	10% Owner	877,606
US:CASM / CAS Medical Systems, Inc.	10% Owner	2,358,636
US:IVTY / Invuity, Inc.	10% Owner	1,690,498
US:VNDA / Vanda Pharmaceuticals Inc.	10% Owner	693,171
US:NVLS / Nivalis Therapeutics, Inc.	Director, 10% Owner	12,300
US:BOLD / Boundless Bio, Inc.	10% Owner	0
US:AXGN / Axogen, Inc.	10% Owner	3,000,000
US:SYRS / Syros Pharmaceuticals, Inc.	10% Owner	0
US:XNPT / XenoPort, Inc.	10% Owner	2,746,650
US:AVXS / AveXis, Inc.	Director, 10% Owner	0
US:EDIT / Editas Medicine, Inc.	10% Owner	0
US:STRM / Streamline Health Solutions, Inc.	10% Owner	1,875,500
US:ALIM / Alimera Sciences, Inc.	10% Owner	728,718
US:CTMX / CytomX Therapeutics, Inc.	10% Owner	0
US:ATRS / Antares Pharma Inc	10% Owner	5,348,776
US:RGNX / REGENXBIO Inc.	10% Owner	0
	10% Owner	0
US:LIFE / aTyr Pharma, Inc.	10% Owner	0
US:ASPX / Auspex Pharmaceuticals, Inc.	10% Owner	0
US:STDY / SteadyMed Ltd.	10% Owner	0
US:NVTA / Invitae Corporation	10% Owner	0
US:AUXL / Auxilium Pharmaceuticals Inc	10% Owner	0
US:DRNA / Dicerna Pharmaceuticals Inc	10% Owner	800,794
US:LOXO / Loxo Oncology, Inc.	10% Owner	0
US:AAVL / Avalanche Biotechnologies, Inc.	10% Owner	0
US:TRIV / TriVascular Technologies, Inc.	10% Owner	0
	Director, 10% Owner	0
US:SOMX / Somaxon Pharmaceuticals, Inc.	10% Owner	514,128
US:NXTM / NxStage Medical, Inc.	10% Owner	2,422,121
US:RIGL / Rigel Pharmaceuticals, Inc.	10% Owner	3,204,167
US:NURO / NeuroMetrix, Inc.	10% Owner	781,833
US:SLXP / Salix Therapeuticals, Inc.	10% Owner	2,941,480
US:CYCC / Cyclacel Pharmaceuticals, Inc.	10% Owner	881,743
US:DVAX / Dynavax Technologies Corporation	10% Owner	0
US:ARNA / Arena Pharmaceuticals Inc	10% Owner	3,238,908

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James E Flynn. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACRS / Aclaris Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACRS / Aclaris Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
There are no known unplanned open-market trades for this insider and security combination